Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.525
Journals
Pharmaceutics
Special Issues
Advances in Age Related Drug Delivery
share announcement

Special Issue "Advances in Age Related Drug Delivery"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 December 2023 | Viewed by 2080

Special Issue Editors

Dr. Nunzio Denora

E-Mail Website
Guest Editor
Department of Pharmacy-Pharmaceutical Sciences, University of Bari “Aldo Moro”, I-70125 Bari, Italy
Interests: drug delivery; drug targeting; age-related formulations
Special Issues, Collections and Topics in MDPI journals
Dr. Mimoza Basholli-Salihu

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Drug Analysis, Faculty of Medicine, University of Prishtina, 10 000 Prishtina, Kosovo
Interests: nano-drug delivery systems; plant extracts; biological activity; enzyme technology; probiotics
Dr. Aida Shala

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Drug Analysis, Faculty of Medicine, University of Prishtina, 10 000 Prishtina, Kosovo
Interests: proteomics; bioinformatics; nano-drug delivery systems; drug analysis; regulatory affairs; neurodegeneration

Special Issue Information

Dear Colleagues,

Age-related drug delivery is very important in drug development. Both drug delivery performance and various age-related physical, mental and physiological changes can affect drug effectiveness and safety in paediatric and geriatric patients. This Special Issue aims to introduce novel drug delivery strategies in paediatric and geriatric patients, such as novel transdermal, nasal, pulmonary and orally dosage forms that provide consistent, precise, timely and more targeted drug delivery. We invite original research articles and reviews on all aspects of age-related drug delivery highlighting the research currently undertaken in the field of paediatric and geriatric drugs for this Special Issue.

We look forward to receiving your contributions.

Dr. Nunzio Denora
Dr. Mimoza Basholli-Salihu
Dr. Aida Loshaj Shala
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • age-related
  • drug delivery
  • paediatric
  • geriatric
  • formulation
  • personalized medicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

get_app
Article
Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2–<7 Years: Results of an Open-Label Randomised Study
by
Juliane Münch
,
Carolin Kloft
,
Madhi Farhan
,
Vladislav Fishman
,
Sining Leng
,
Hans Martin Bosse
and
Viviane Klingmann
Pharmaceutics 2023, 15(2), 701; https://doi.org/10.3390/pharmaceutics15020701 - 20 Feb 2023
Viewed by 755
Abstract
This single-centre, open-label, randomised, parallel-group study assessed the acceptability, swallowability, palatability, and safety of film-coated, 3 mm diameter mini-tablets in children aged ≥2–<7 years. In total, 300 participants were randomised (2:2:1:1) to receive a single oral administration of 16 (group A) or 32 [...] Read more.
This single-centre, open-label, randomised, parallel-group study assessed the acceptability, swallowability, palatability, and safety of film-coated, 3 mm diameter mini-tablets in children aged ≥2–<7 years. In total, 300 participants were randomised (2:2:1:1) to receive a single oral administration of 16 (group A) or 32 (group B) mini-tablets with soft food or 16 (group C) or 32 (group D) mini-tablets with water. Children in each group were stratified by age group (2–<3 years; 3–<4 years; 4–<5 years; 5–<6 years; and 6–<7 years). Groups C and D were pooled for statistical analyses. The rates of acceptability (swallowed ≥80% of the mini-tablets with or without chewing), swallowability (swallowed all mini-tablets without chewing or any leftover), and palatability (positive/neutral responses) were ≥80.0%, ≥42.0%, and ≥82.0%, respectively, across the study groups. No marked differences were observed between groups or across age groups. No adverse events or issues of clinical relevance with deglutition were reported. Mini-tablets taken with soft food or water provide a suitable method for administering medicines to children aged ≥2–<7 years. This study was registered in the German Clinical Trial Register (No. DRKS00024617). Full article
(This article belongs to the Special Issue Advances in Age Related Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

get_app
Review
Quercetin and Its Nano-Formulations for Brain Tumor Therapy—Current Developments and Future Perspectives for Paediatric Studies
by
Aida Loshaj Shala
,
Ilaria Arduino
,
Mimoza Basholli Salihu
and
Nunzio Denora
Pharmaceutics 2023, 15(3), 963; https://doi.org/10.3390/pharmaceutics15030963 - 16 Mar 2023
Viewed by 955
Abstract
The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. [...] Read more.
The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. The current treatment protocol consists of surgery, followed using synthetic drugs and radiation. However, the efficacy of these protocols is associated with side effects, poor prognosis and with a median survival of fewer than two years. Recently, many studies were focused on applying plant-derived products to manage various diseases, including brain cancers. Quercetin is a bioactive compound derived from various fruits and vegetables (asparagus, apples, berries, cherries, onions and red leaf lettuce). Numerous in vivo and in vitro studies highlighted that quercetin through multitargeted molecular mechanisms (apoptosis, necrosis, anti-proliferative activity and suppression of tumor invasion and migration) effectively reduces the progression of tumor cells. This review aims to summarize current developments and recent advances of quercetin’s anticancer potential in brain tumors. Since all reported studies demonstrating the anti-cancer potential of quercetin were conducted using adult models, it is suggested to expand further research in the field of paediatrics. This could offer new perspectives on brain cancer treatment for paediatric patients. Full article
(This article belongs to the Special Issue Advances in Age Related Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop